Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of STAR-0215 in adults with hereditary angioedema
ISRCTN17914189Phase 2Active, not recruiting
- Sponsor
- Astria Therapeutics
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of navenibart in hereditary angioedema (HAE) (3 arms), sponsored by Astria Therapeutics. Primary endpoint: Number of participants experiencing treatment-emergent adverse events. Started Sep 2023; status: active, not recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on ISRCTN17914189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17914189.